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Background: Systemic neovascularization of the lung during chronic ischemia has been observed in all mammals
studied. However, the proteins that orchestrate the complex interaction of new vessel growth and tunneling
through lung tissue matrix have not been described. Although previous work has demonstrated the CXC
chemokines are essential growth factors in the process of angiogenesis in mice and rats, key matrix proteins have
not been identified.
Methods: Since the degradation of chemokines has been shown to be dependent on metalloproteinases (MMP),
we first surveyed gene expression patterns (real time RT-PCR) of several lung matrix proteins in DBA/J (D2) mice
and C57Bl/6 (B6) mice, strains known to have divergent parenchymal responses in other lung disease models. We
studied changes in the time course of MMP-12 activity in D2 and B6 mice. Functional angiogenesis was determined
14 days after the onset of complete left lung ischemia induced by left pulmonary artery ligation (LPAL), using
fluorescent microspheres.
Results: Our results confirmed higher levels of MMP-12 gene expression in D2 mice relative to B6, which
corresponded to a phenotype of minimal systemic angiogenesis in D2 mice and more robust angiogenesis in B6
mice (p < 0.01). MMP-12 activity decreased over the course of 14 days in B6 mice whereas it increased in D2 mice
(p < 0.05). MMP-12 was associated largely with cells expressing the macrophage marker F4/80. Genetic deficiency of
MMP-12 resulted in significantly enhanced neovascularization (p < 0.01 from B6).
Conclusion: Taken together, our results suggest macrophage-derived MMP-12 contributes to angiostasis in the
ischemic lung.
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Systemic angiogenesis occurs in mice during chronic
pulmonary ischemia after complete left pulmonary artery
obstruction [1]. The global gene expression profile and
subsequent protein validation demonstrated that the
ELR + CXC chemokines are upregulated early after the
onset of ischemia, and are essential to the process of sys-
temic neovascularization of the lung [2,3]. These obser-
vations provide further support to the accumulating
body of evidence demonstrating that the pro-angiogenic* Correspondence: wagnerem@jhmi.edu
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distribution, and reproduction in any mediumprotein-2 alpha, mCXCL2; keratinocyte-derived chemo-
kine, mCXCL1; and lipopolysacharide-induced chemo-
kine, mCXCL3, respectively) in the mouse contribute to
the process of new systemic vessel growth and invasion
into pulmonary parenchyma [4-6]. However, proteases
responsible for degradation of these key growth factors
are unknown with respect to the overall angiogenic
response.
Interestingly, Dean and colleagues [7] have shown that
several CXC chemokines are degraded by matrix metal-
loproteinases (MMP). Specifically, macrophage-derived
matrix MMP-12 (macrophage elastase) was shown to
cause proteolysis at the terminal E-LR (Glu-Leu) motif
and inactivate both MIP-2α and KC, but not LIX [7].
MMP-9 (gelatinase B) was shown to increase the
chemotactic activity of IL-8 (CXCL8) 10-fold in humantral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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processing of growth factors by MMP is not unique to
the CXC chemokines as Ebrahem and colleagues showed
that MMP-9 was essential for release of sequestered
VEGF, but was also involved in the proteolysis of this
ubiquitous growth factor [9]. Additionally, MMP-12 has
been shown to be critical to the process of plasminogen
degradation into the anti-angiogenic factor angiostatin
[10]. These observations highlight the importance of
MMP in regulating the activity of key proteins that im-
pact neovascularization. However, the role of MMP in
modulating angiogenesis has long focused on their im-
portance in degrading extracellular matrix in advance of
new vessel growth [11,12]. In this capacity, the MMP
family of zinc binding, Ca2+-dependent neutral endopep-
tidases can act individually or together to degrade extra-
cellular matrix. Of these proteins, MMP-2 (gelatinase A)
and MMP-9 have been shown to work in tandem and
appear to be essential during the early stages of angio-
genesis in several models of hypoxic, ischemia-induced
angiogenesis to promote tissue remodeling as well as
growth factor activation [11,13]. Plasma proteins and the
tissue inhibitors of metalloproteinases (Timp) are key
endogenous regulators of MMP. A variety of other
matrix proteins and protein fragments have been shown
to induce both inflammation and angiogenesis in several
models of ischemia-induced neovascularization [14,15].
Given the inherent complexity of matrix changes dur-
ing tissue ischemia, in vivo models may appear impene-
trable. However, examination of mouse strain-dependent
differences in gene expression patterns has yielded im-
portant information concerning complex changes in the
lung during aging [16,17], injury and repair [18] and
lung provocation [19-21]. Previous reports describe a
difference in matrix gene expression patterns between
DBA/2J (D2) and C57BL/6J (B6) mice in aging lung
[16,17]. Consequently, in the current study, we used a
similar strategy and surveyed changes in a panel of
matrix-relevant genes in different mouse strains during
ischemia. We subsequently focused on MMP-12 activity
early and late in the process of neovascularization to de-
termine potential mechanisms of response. Our results
demonstrate that there are substantial differences in the
rate of lung angiogenesis between B6 and D2 strains and
that MMP-12 is overall angiostatic during lung ischemia.
Methods
Animals
Male DBA/2J (D2) and C57BL/6J (B6) inbred mice and
MMP-12 deficient mice (all 5-6 weeks of age) were pur-
chased from The Jackson Labs (JAX, Bar Harbor, ME).
The same B6 mice served as the background strain for
MMP-12-/- mice. All mice were housed in an animal fa-
cility at the Johns Hopkins Asthma and Allergy Center.The room was maintained at a temperature of 21 ± 1°C
(mean ± SEM) and with a 12-h light/dark cycle. Regular
rodent chow and tap water were provided ad libitum.
All experiments were conducted with approval from the
Animal Care and Use Committee of the Johns Hopkins
University Medical Institutions.
Left pulmonary artery ligation (LPAL)
Surgery was performed as previously described [2,3].
Mice were anesthetized (2% isoflurane in air), intubated,
and ventilated with the anesthetic/gas mixture. A left lat-
eral thoracotomy was performed (third intercostal
space), the left pulmonary artery was separated from the
airway and ligated with silk suture. The thoracotomy
was closed and mice were allowed to recover. Surgical
control mice (sham) were treated the same as experi-
mental mice in all respects except they lacked LPAL.
Naïve mice were euthanized by cervical dislocation as
were all other mice at specific time points for tissue har-
vest or evaluated 14 days after LPAL for functional
angiogenesis (blood flow determination).
Real time RT-PCR
Using standard techniques, total RNA isolation was pre-
pared from left lungs from each group of mice (n = 3
mice per strain/time points: naïve, 3 d, 14 d) using the
TRIzol reagent (Invitrogen, Carlsbad, CA) following the
manufacturer’s instructions. Total RNA was isolated
using the RNeasy Mini Kit (Qiagen, Valencia, CA), and 3
μg of total RNA was reverse transcribed to complemen-
tary DNA (cDNA) using random primers and Multi-
Scribe reverse transcriptase (Applied Biosystems, Foster
City, CA). Using 100 ng of cDNA as a template, quanti-
fication was performed by an ABI Prism 7000 Sequence
Detector (Applied Biosystems) using the TaqMan 5' nu-
clease activity from the TaqMan Universal PCR Master
Mix, fluorogenic probes (Applied Biosystems) and oligo-
nucleotide primers (Invitrogen). TaqMan assays were
repeated twice for each of 15 selected genes related to
lung extracellular matrix in each lung sample. The
selected genes were based on previous published results
[16,17] and included: procollagen I (Col1a1), III
(Col3a1), and VI (Col6a3), elastin (Eln), fibrillin 1 (Fbn1)
and fibronectin 1 (Fn1). Protease genes included: matrix
metalloproteinase 2 (MMP-2), 9 (MMP-9), 12 (MMP-12),
and 14 (MMP-14) and cathepsin K (Ctsk). Anti-protease
genes included: tissue inhibitor of metalloproteinase 1
(Timp1), 2 (Timp2), 3 (Timp3) and 4 (Timp4). The
mRNA expression levels of all samples were normalized
to the levels for the housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) from the same
sample, and relative fold changes were calculated using
the 2-ΔΔCT method [16,17]. To confirm B6 and D2
strain differences in naïve lung tissue, results of each
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enced to B6 mice.
MMP-12 activity
The time course of MMP-12 activity was measured in
B6 (n = 3 mice/time point) and D2 (n = 3 mice/time
points: 0 hr, 7 d, 10 d, 14 d) left lung tissue lysates using
the Sensolyte 520 MMP-12 assay kit (Anaspec, San Jose,
California, USA) according to the manufacturer’s
instructions. Fluorescence, resulting from enzyme-
mediated conversion of the fluorogenic substrates, was
measured in a Novostar plate reader (BMG Labtech,
Durham, NC) using black 96-well plates (Corning,
Corning, NY) at excitation/emission wavelengths of
490/520 nm respectively. Substrate-only samples were
included for background subtraction purposes. All
measurements were performed in duplicate.
MMP-12 lung cell localization
The cell source of MMP-12 was evaluated using immu-
nostaining followed by flow cytometry and histochemis-
try. Freshly extracted left lung mouse tissue (n = 3/time
point/strain) was minced and digested using previously
described methods [22]. Nonspecific binding sites were
blocked (Fc Block; BD Pharmingen, San Jose, CA), cells
were incubated with a pan macrophage marker (APC la-
beled F4/80; Ebioscince, San Diego, CA), and LIVE/
DEADW Fixable Blue fluorescent reactive dye (Invitrogen,
Carlsbad, CA) and fixed, permeabilized, and stained with
a monoclonal antibody for MMP-12 which identifies 3
isoforms (54/45/22 kDA MW; Epitomics, Burlingame,
CA ). Flow cytometry was performed using a FACSAria
(Becton Dickinson, Franklin Lanes, NJ), and data ana-
lyzed with FlowJo software (Treestar Inc, Ashland, OR).
In a separate series of mice (n = 2/time point/strain),
lungs were inflated with Optimal Cutting Temperature
Compound (OCT), frozen in OCT and sectioned. Frozen
sections were blocked and stained with antibody against
MMP-12 and F4/80 and 4, 6-diamidino-2-phenylindole
(DAPI, Invitrogen, Carlsbad, CA). Sections were visua-
lized and photographed using an Olympus IX51 micro-
scope and SensiCam high performance digital camera
(Cooke, Auburn Hills, MI).
Protein evaluation
Changes in lung MIP-2α protein were evaluated in B6
mice (n = 6), D2 mice (n = 4), and MMP-12-/- mice
(n = 6). Twenty-four hrs after LPAL, anesthetized mice
were euthanized, and the upper left lung and the upper
right lung were rapidly excised and frozen. This time
point was selected based on previous results demonstrat-
ing that chemokine expression was maximum and
trended downward at later time points [3]. Lung samples
were weighed, homogenized, and aliquoted. MIP-2α wasdetermined by ELISA (Duoset Mouse MIP-2, ELISA kit;
R&D Systems, Minneapolis, MN) and normalized to
total sample protein (BCA protein assay kit; Pierce,
Rockford, IL).
Angiostatin was measured in additional mice (6 mice/
B6 and D2 mice, 3 MMP-12 mice) 14 days after LPAL.
This time point was selected based on late changes in
MMP-12 activity and the expectation that an angiostatic
factor would be most abundant late after LPAL. Lungs
were obtained as described above, angiostatin deter-
mined by ELISA (Angiostatin ELISA kit; USCN Life Sci-
ence, Wuhan, China) and normalized to total sample
protein (BCA protein assay kit; Pierce, Rockford, IL).
Angiogenesis assessment
After mice were anesthetized and intubated, the extent
of neovascularization was determined by measuring sys-
temic blood flow to the left lung 14 days after LPAL
using fluorescent microspheres (n = 4-5/group; Invitrogen,
Eugene, OR) [23]. The carotid artery was cannulated and
360,000 microspheres (10 μm) were infused with a pump.
Mice were sacrificed by exsanguination and the left lung
was excised. Microspheres lodged in the left lung were
quantified after tissue digestion and fluorescent dye extrac-
tion, and the number calculated from a standard curve.
Data are presented as the number of microspheres deli-
vered to the left lung relative to total infused (functional
angiogenesis, %).
Statistical analysis
The results reported in the figures and tables are means
(± SEM). For RT-PCR values, multiple Student t-tests
were performed to establish significance between group
means, and were considered statistically significant at
p < 0.01. For all other analyses, p < 0.05 was the accepted
significance level. Angiogenesis was evaluated by
ANOVA followed by Newman-Keuls Comparison of
means. A 2-way ANOVA was used to evaluate time
dependent changes in MMP-12 activity, MMP-12+ F4/
80+ cells and MIP-2α levels.
Results
Strain variation in gene expression profiles
To confirm baseline differences in select lung structural,
protease and anti-protease genes between D2 and B6
mice, we measured gene expression profiles in naïve
lung tissue (Table 1). In this analysis we applied the cri-
teria of requiring at least a two-fold increase at a signifi-
cance level of p < 0.01. As compared to levels in B6
mice, the gene expression in D2 mice was significantly
lower for the Eln gene. The expression levels of MMP-2
and MMP-12 genes were significantly higher in D2 mice
by more than respectively, 20- and 3-fold on average
relative to B6 mice. There were no detectable differences
Table 1 Changes in matrix protein gene expression in B6 vs D2 mice
B6 D2
3d LPAL 14d LPAL Naïve 3d LPAL 14d LPAL
Structural genes
Col1a1 1.3 ± 0.1 1.4 ± 0.2 1.1 ± 0.1 2.1 ± 0.6 1.6 ± 0.2
Col3a1 1.4 ± 0.0 1.2 ± 0.2 1.6 ± 0.0 1.7 ± 0.1 1.7 ± 0.2
Col6a3 1.3 ± 0.1 1.7 ± 0.2 1.1 ± 0.2 1.7 ± 0.4 2.2 ± 0.5
Eln 1.8 ± 0.2 3.0 ± 0.5* 0.5 ± 0.1* 2.4 ± 0.8 3.5 ± 0.5*
Fbn1 1.1 ± 0.2 1.1 ± 0.1 0.9 ± 0.1 2.2 ± 1.0 1.4 ± 0.1
Fn1 1.3 ± 0.1 1.3 ± 0.2 1.3 ± 0.3 1.5 ± 0.2 1.3± 0.1
Protease genes
MMP-2 1.0 ± 0.1 1.9 ± 0.2* 20.1 ± 1.0* 0.9 ± 0.2 1.5 ± 0.1
MMP-9 1.3 ± 0.2 0.5 ± 0.2 0.9 ± 0.1 1.3 ± 0.3 0.4 ± 0.0*
MMP-12 3.6 ± 0.7* 1.7 ± 0.1 3.2 ± 0.5* 2.0 ± 0.8 2.9 ± 1.2
MMP-14 2.0 ± 0.1* 1.5 ± 0.2 1.0 ± 0.1 2.7 ± 0.8 2.0 ± 0.3
Ctsk 1.3 ± 0.1 1.8 ± 0.3 1.6 ± 0.1 1.1 ± 0.2 1.7 ± 0.2
Anti-protease genes
Timp1 8.8 ± 0.6* 1.5 ± 0.2 0.8 ± 0.0 19.6 ± 2.9* 3.8 ± 0.1*
Timp2 0.7 ± 0.1 0.9 ± 0.0 1.5 ± 0.1 0.8 ± 0.2 1.5 ± 0.1
Timp3 0.7 ± 0.1 1.0 ± 0.0 1.7 ± 0.2 1.1 ± 0.3 2.4 ± 0.2*
Timp4 0.5 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 1.2 ± 0.1 2.5 ± 0.4*
Expression of matrix-associated genes (* indicates p < 0.01). All comparisons were made versus B6 naïve left lungs.
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These results confirm some previous observations
[16,17] suggesting inherent differences in the expression
of several genes between D2 and B6 mouse strains that
might influence lung structure. To determine whether
gene expression profiles changed after the onset of is-
chemia, left lungs from D2 and B6 mice were studied 3
days after LPAL, a time of active neovascularization [24]
and again 14 days after LPAL when a neovasculature is
fully established [25]. Table 1 shows matrix gene expres-
sion relative to naïve B6 lungs, 3 days and 14 days after
LPAL. Both strains showed a significant increase in Eln
14 days after LPAL. However, with regard to protease
genes, MMP-12 and MMP-14 were significantly up-
regulated in LPAL B6 mice and not in D2 mice 3 days
after LPAL. The anti-protease genes were more substan-
tially upregulated in D2 mice after ischemia compared
with B6 mice. Mice undergoing sham surgery showed no
significant change from naïve lungs (data not shown).
MMP-12 lung cell localization
Figure 1 shows a representative frozen section of a left
lung 14 d after LPAL from a B6 mouse (400x magnifica-
tion). Prominent staining of F4/80+ macrophages shows
co-localization with MMP-12+ cells within the lung par-
enchyma. The antibody to MMP-12 recognized both ac-
tive and inactive isoforms of MMP-12. Extensive review
of histologic sections did not reveal any consistentMMP-12+ F4/80- cells. Quantification of strain and
time-dependent association of MMP-12+ F4/80+ cells in
the lung after LPAL was analyzed in additional mice.
Flow cytometric analysis of dispersed mouse lungs (n = 3
mice/strain/time point) demonstrated that MMP-12 was
predominantly associated with F4/80+ macrophages in
B6 (80 ± 6%) and D2 mice (78 ± 4%) at the onset of is-
chemia (0 hr). These values did not alter when measured
14 d after LPAL in B6 (74 ± 7%) or D2 mice (74 ± 25%).
MMP-12 activity
Because of the baseline differences observed in MMP-12
expression and early increase in MMP-12 expression in
ischemic B6 mice, the time course of MMP-12 protease
activity was measured in the two strains. Figure 2 shows
the slow decline of MMP-12 activity in B6 mice and the
slow increase in MMP-12 activity in D2 mice over the
course of 14 days after LPAL. This time-dependent
change in MMP-12 activity was statistically different be-
tween strains (F-stat = 3.43, p = 0.047).
Strain variation in angiogenesis
Changes in systemic neovascularization of the left lung
14 days after LPAL are shown in Figure 3. Functional
angiogenesis evaluated by systemic perfusion of the left
lung is shown for individual B6, D2, and MMP-12-/-
mice (p < 0.001). This functional assessment of angio-
genesis in B6 mice showed an average systemic
F4/80 MMP-12
DAPI Composite
Figure 1 Histologic section of left lung from C57 mouse 14 d after LPAL (400 x magnification). MMP-12+ cells (red) are co-localized with
F4/80+ macrophages (green). DAPI (blue) was used to show all cell nuclei. Composite shows co-localization of staining with arrows indicating
several of the MMP-12+ F4/80+ cells.
*
Figure 2 MMP-12 activity (slope/min/mg) over the 14 d time
course after ischemia in B6 and D2 mice (n = 3 mice/time
point). MMP-12 activity in B6 mice decreases with time, while it
increases with time in D2 mice. This time-dependent change in
MMP-12 activity is significantly different between strains; p < 0.05.
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output, which was equivalent to previously reported
values for this time point after LPAL [1,2]. This index of
functional angiogenesis was significantly higher in B6
mice compared to D2 mice which averaged 0.8 ± 0.4%
of cardiac output (p < 0.01). Furthermore, angiogenic
perfusion to the left lung of MMP-12-/- mice 14 days
after LPAL was significantly greater than both B6 and
D2 mice averaging 5.0 ± 0.3% (p < 0.01). Thus, the col-
lective strain variation in functional angiogenesis among
the three groups shows that neovascularization is the
lowest in D2 mice and the highest in MMP-12-/- mice.
Protein
Left lung homogeneate was assessed 24 hrs after
LPAL to determine if strain-dependent differences
existed in the level of the proangiogenic chemokine,
MIP-2α. Left lung values are compared to paired right
lung controls in B6, D2, and MMP-12-/- mice and are
shown in Figure 4. As previously reported, there was a
significant difference in left lung MIP-2α protein versus
right lung in B6 mice [26]. This difference was also
evident in D2 mice. However, there were no significant
differences among left lungs of the three strains or
among right lungs at this time point after LPAL.
Lung homogenates were assayed 14 days after LPAL to
determine if strain-dependent differences existed in thelevel of the MMP-12-dependent anti-angiogenic protein
angiostatin. No significant differences between left and
right lung angiostatin values were seen, nor were there
differences in the left lungs across strains (Figure 4).
Angiostatin level for left lungs of B6 mice averaged 5.6 ±




















Figure 3 Functional angiogenesis (% cardiac output) in three
mouse strains. Changes in lung neovascularization were assessed
by measuring left lung perfusion 14 d after LPAL. Each point
represents one mouse. Each group was significantly different from
the other with angiogenesis greatest in MMP-12-/-, followed by B6,
and the lowest level was observed in D2 mice (p < 0.01 for all
comparisons).
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lung protein.
Discussion
The role of matrix proteins during angiogenesis has been
studied yet results demonstrate that key regulators are
highly organ-specific [27]. Angiogenic growth factors are
unique to local environmental conditions. In the ische-
mic, ventilated lung, hypoxia-inducible factors appear
not to play a major role in systemic vascularizationangiostatin






















Figure 4 MIP-2α protein and angiostatin in lung homogenates
after LPAL in the three mouse strains normalized to total lung
protein. A significant increase in MIP-2α protein was observed 24
hrs after LPAL in left lungs of B6 and D2 mice relative to paired right
lungs (p < 0.05). No strain-dependent differences in left lungs were
observed (n = 4-6 mice /group). No strain-dependent differences
were observed in the level of left lung angiostatin 14 d after LPAL (6
mice B6 and D2 mice, 3 MMP-12 mice).whereas inflammatory cytokines have been shown to be
critical to the process of new vessel growth [3]. Several
metalloproteinases have been implicated in the metabol-
ism of growth factors [7-9]. However, the importance of
matrix proteins in the process of systemic neovasculari-
zation of the lung has not been reported. In the present
study we relied on previously reported, strain-dependent
differences in matrix proteins to probe the importance
of select proteases to the process of systemic neovascu-
larization. Our results identify MMP-12 as an angiostatic
factor in the ischemic lung that appears to modulate the
extent of systemic neovascularization in this non-
hypoxic environment. However, the specific mechanisms
by which the activity of MMP-12 limits neovasculariza-
tion remain unclear.
Ischemic injury in the lung has been shown to result
in permeability changes [25], inflammation [26], and
subsequent systemic neovascularization of the lung
[25,26]. Systemic angiogenesis during pulmonary vascu-
lar ischemia includes the growth of bronchial and inter-
costal arteries and has been documented in dogs [28,29],
sheep [30], rats [31], mice [1], and in patients with
chronic pulmonary thromboembolism [32]. Yet the
complex process of tissue repair including the tunneling
of proliferating vessels is not known. New endothelial
networks are established in response to chemotactic
stimuli. Within the lung, this repair likely includes endo-
thelial proliferation and reorganization of existing cells
and structures. To begin to dissect this complex process,
we first surveyed candidate genes known to be involved
in other forms of lung injury and we studied them in
two previously reported, divergent mouse strains [16,17].
We also measured angiogenesis in these two strains and
found that D2 mice showed a significantly reduced
angiogenic phenotype compared with B6 mice (Figure 3).
Systemic perfusion of the left lung 14 days after the
onset of total left lung ischemia in D2 mice was on aver-
age, 30% of that observed in B6 mice. Based on this find-
ing and previously published data demonstrating the
time course of neovascularization [1], we surveyed
matrix gene expression profiles 3 days after the onset of
ischemia when active changes were expected and com-
pared them to expression levels 14 days after LPAL
when a new network was established. Of the 15 genes
surveyed, MMP-12 was confirmed to be significantly
greater in D2 mice than in B6 mice at baseline in naïve
mice. Furthermore, MMP-12 expression increased in B6
mice by 3 days. Although a complete time course was
not obtained, we showed that MMP-12 was changing, it
was expressed differently but in both strains, and Timp1,
the anti-protease regulator of MMP-12 increased in both
strains. Thus, we hypothesized that MMP-12 exerted an
important influence on systemic angiogenesis in the lung
during ischemia. While transcription profiles appeared
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would be predictive of protein activity. Additionally,
others had shown MMP-12 altered the metabolism of
growth factors [7] as well as angiostatic factors [10].
Subsequent experiments focused specifically on the
effects of MMP-12 in this model.
In an effort to evaluate the functional relevance of the
changes in gene expression, we measured the time
course of MMP-12 activity after ischemia in the lung.
No differences were seen in MMP-12 activity between
the D2 and B6 mice at the 0 hr time point (immediately
after LPAL). However, incremental decreases in MMP-
12 activity were observed over the course of 14 days only
in B6 mice. D2 mice showed a small increase in MMP-
12 activity by 14 days after LPAL. Statistical analysis
showed a significant interaction between the effects of
time and strain from immediately after the onset of is-
chemia to the time when a functional systemic bed was
established. Over the course of 14 days, MMP-12 activity
differed between the 2 mouse strains. The activity profile
did not directly parallel gene expression pattern yet was
consistent with the hypothesis that MMP-12 activity
might contribute to the decrease in angiogenesis
observed in D2 compared to B6 mice in this ischemic
model.
In an effort to localize the predominant source of
MMP-12 in the lung, we used immunohistochemistry
and flow cytometry. Histologic sections demonstrated
co-localization of MMP-12 with F4/80+ macrophages.
No significant differences were seen in the percent of
live cells in the lung expressing MMP-12 and F4/80 be-
tween strains or over time. However, the antibody used
for MMP-12 recognized both active and inactive iso-
forms of MMP-12 and likely accounts for this observa-
tion. Furthermore, it highlights the overall importance of
measuring the activity of MMP-12 throughout the time
course of ischemia.
Studying angiogenesis in mice genetically deficient in
MMP-12 provided a phenotype for comparison to D2
and B6, 14 days after LPAL. Figure 3 shows the differ-
ence in functional angiogenesis in MMP-12-/- mice com-
pared to the two other strains. MMP-12-/- mice
exhibited an 80% increase in perfusion of the left lung
relative to the B6 background strain. This observation,
that MMP-12 deficiency allowed for greater perfusion
and neovascularization, is consistent with the MMP-12
activity data in the two strains. The greatest MMP-12
activity is associated with the lowest angiogenic out-
come. These findings establish that MMP-12 is overall
angiostatic in the ischemic lung.
Two series of experiments were performed in an at-
tempt to determine the mechanism by which MMP-12
activity might impact angiogenesis in the ischemic
mouse lung. The first series was based on the findings ofDean and colleagues that demonstrated that MMP-12
was critical for the metabolism and inactivation of both
MIP-2α and KC [7]. Previous work from our laboratory
has shown these chemokines to be prominent, pro-
angiogenic growth factors that increased by 24 hrs after
the onset of lung ischemia [3]. Therefore, we measured
MIP-2α at this single time point in the three mouse
strains. Our results confirmed significant differences be-
tween left and right lungs but no differences between
strains. This lack of difference between D2 and B6 mice
was consistent with the observation of similar MMP-12
activity levels initially at the onset of ischemia. Addition-
ally, MMP-12-/- mice showed no significant difference in
MIP-2α levels suggesting that this proteolytic function is
not operative in the lung or that MIP-2α levels exceeded
the capacity of this metabolic pathway at this time point.
Since there was a slow decline in MMP-12 activity in
the B6 mice and an increased level in the D2 mice over
the course of 14 days of ischemia, we speculated in a
second series of experiments that increased MMP-12 ac-
tivity contributed directly to an angiostatic protein that
slowed angiogenesis in D2 mice. Cornelius and cowor-
kers showed that MMP-12 is essential for the formation
of angiostatin, an important anti-angiogenic by-product
of plasminogen metabolism, which inhibits endothelial
cell proliferation [10]. Other clinical studies have arrived
at the same conclusion regarding the inhibitory role
MMP-12 plays in hindering angiogenesis [10,33,34].
Thus we measured angiostatin levels in the lungs of all
three strains 14 days after LPAL. We reasoned that at
this time point we should see differences in levels if
angiostatin had a slowing effect. Results showed similar
levels in left and right lungs of all mice. Thus, we con-
cluded that either the methods to measure angiostatin
(ELISA) were inadequate, the time point selected was
not optimal for angiostatin detection, or angiostatin is
not important in this model.
We focused our studies on the role of MMP-12 during
ischemia-induced angiogenesis since this metalloprotei-
nase has been reported to be involved with the metabol-
ism of growth/angiostatic factors. However, there were
large significant differences in Eln (decreased), MMP-2
(increased) in D2 naïve lungs relative to B6 naïve lungs,
and increases in Timp1 during ischemia in both strains.
Each has been associated with changes in vascularization
and might play a regulatory role during ischemia. Regu-
lated elastin production and deposition have been shown
to be critical for normal neonatal vasculogenesis of the
pulmonary vasculature [35]. Supportive of the finding
that lung structural components impact angiogenesis
during ischemia, our laboratory showed hyaluronan frag-
ments significantly increase systemic angiogenesis in the
adult [23]. Additionally, the role of Timp1 has been
shown to be anti-angiogenic in a variety of models
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[7,36-38]. Thus, these and other matrix-associated gene
products require further evaluation in the ischemic lung.
Conclusion
In summary, we used gene expression profiling of a
panel of matrix-specific genes, angiogenesis quantifica-
tion, and divergent mouse strains to identify gene pro-
ducts that may play a role in directing the course of
systemic neovascularization of the lung after ischemic
injury. Our results show that MMP-12 is angiostatic in
this ischemic, non-hypoxic lung injury model. Strategies
to activate this metalloproteinase may provide thera-
peutic opportunities to prevent excessive neovasculariza-
tion in inflammatory lung disease.
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